



Opioid Receptor, Mu 1 (OPRM1) Genotype
for Naltrexone Efficacy, Saliva

Patient ID SA00062781	Patient Name TESTINGRNV, OPRMO AB	Birth Date 1980-01-21	Gender F	Age 33
Order Number SA00062781	Client Order Number SA00062781	Ordering Physician Client, Client	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 24 Sep 2013 09:12		

OPRM1 Genotype, Naltrexone, Saliva

OPRM1 Result

G/G

MCR

OPRM1 Reviewed by

Jamie Bruflat

MCR

OPRM1 Interpretation

Homozygous OPRM1 355G/G [Asp/Asp]. This individual is homozygous for the OPRM1 355G allele which encodes for the Aspartic acid/Aspartic acid genotype. The Aspartic acid allele has been associated with better response to naltrexone treatment in alcoholics; including lower rate of relapse and a longer time to return to heavy drinking.

ADDITIONAL INFORMATION

Direct polymorphism analysis of the OPRM1 355A>G [Asn102Asp] polymorphism is performed by a Polymerase Chain

MCR

Reaction (PCR) based 5'-nuclease assay using fluorescently labeled detection probes. Historically the mutation has been referred to as OPRM1 118A>G [Asn40Asp]. This DNA testing will not detect all the known mutations and polymorphisms of OPRM1. Absence of mention of a specific gene mutation or polymorphism does not rule out the possibility that a patient has that or another variation that can impact the function of this receptor, drug response or drug side effects.

CAUTIONS:

If the patient has had an allogeneic blood or marrow transplant or a recent (i.e. less than 6 weeks from time of sample collection) heterologous blood transfusion these results may be inaccurate due to the presence of donor DNA. For research use only.

Received: 25 Sep 2013 14:00

Reported: 25 Sep 2013 14:21

Performing Site Legend

Code	Laboratory	Address
MCR	Mayo Clinic Dept. of Lab Med and Pathology	200 First Street SW, Rochester, MN 55905